Faculty Development Competitive Research Grant Program 2019-2021
Our goal is to determine whether the Crizotinib and iCRT3 combination enhances the anti-cancer effects of either Crizotinib or iCRT3 alone in human CRPC cells by targeting cancer stem-like cells and to define the mechanism by which combinatorial drugs inhibited nuclear MET/β-Catenin/ AR and novel signaling in human CRPC cells.
|Short title||Targeting prostate cancer stem cell|
|Acronym||Prostate cancer drug target|
|Effective start/end date||1/31/19 → 9/30/21|
- Prostate cancer
- Experimental therapy